SCHEMBL1461676

SCHEMBL1461676

CC1(C)C(=O)NC(=O)N1c1ccccc1

nearest known ligand 0.47

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
AR P10275 4/20 0.47
MMP13 P45452 1/20 0.43
PDK2 Q15119 1/20 0.41
PDK4 Q16654 1/20 0.41
MMP2 P08253 1/20 0.41
MMP9 P14780 1/20 0.41
ALDH1A1 P00352 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2C9 P11712 1/20 0.41
CYP2C19 P33261 1/20 0.41
GSK3A P49840 2/20 0.40
GSK3B P49841 2/20 0.40
GAA P10253 1/20 0.40
ELANE P08246 2/20 0.39
CACNA1B Q00975 1/20 0.39
APBA1 Q02410 1/20 0.39
HTR6 P50406 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30393814 0.82 GRK5 (0.46) MMP13PDK2PDK4MMP2MMP9
SCHEMBL25248135 0.79 AR (0.49) ARMMP13MMP2GSK3AGSK3B
SCHEMBL11838692 0.79 AR (0.53) ARMMP13MMP2MMP9ALDH1A1
SCHEMBL25248589 0.79 AR (0.57) ARMMP13ALDH1A1GSK3AGSK3B
SCHEMBL25249887 0.77 ALDH1A1 (0.51) ARALDH1A1GSK3AGSK3BGAA
SCHEMBL25258942 0.77 AR (0.55) ARMMP2ALDH1A1GAA
SCHEMBL30381901 0.77 AR (0.55) ARMMP2ALDH1A1GAA
SCHEMBL30382173 0.77 ALDH1A1 (0.51) ARALDH1A1GSK3AGSK3BGAA
SCHEMBL11465842 0.75 AR (0.68) ARCYP1A2CYP2C9CYP2C19ELANE
SCHEMBL10338930 0.75 MGLL (0.53) ARPDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12570646-B2 Compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2026-03-10 US disclosed
CN-116033899-B Novel compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same 株式会社 钟根堂 2024-11-05 CN disclosed
US-20230295142-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-09-21 US disclosed
US-20230295142-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-09-21 US disclosed
US-20230295142-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME CHONG KUN DANG PHARMACEUTICAL CORP. (KR) 2023-09-21 US disclosed
EP-4208461-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME Chong Kun Dang Pharmaceutical Corp. (KR) 2023-07-12 EP disclosed
CN-116033899-A Novel compounds as inhibitors of histone deacetylase 6 and pharmaceutical compositions comprising the same 株式会社 钟根堂 2023-04-28 CN disclosed
EP-3103797-B1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN INC (US) 2019-04-10 EP disclosed
EP-3103797-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2016-12-14 EP disclosed
EP-2776403-B1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN INC (US) 2016-09-14 EP disclosed
EP-1144366-A3 USE OF ANDROGEN RECEPTOR SUPPRESSORS BIOPHYSICA, INC. (US) 2003-06-04 EP disclosed
WO-2003043983-A1 PIPERAZINE DERIVATIVES DESTABILISING ANDROGEN RECEPTORS SCHERING AKTIENGESELLSCHAFT (DE) 2003-05-30 WO disclosed
WO-2001058855-A9 USE OF ANDROGEN RECEPTOR SUPPRESSORS BIOPHYSICA INC (US) 2002-10-31 WO disclosed
US-6472415-B1 Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes BIOPHYSICA, INC. 2002-10-29 US disclosed
EP-1169301-A1 A TOPICAL ANTIANDROGEN FOR HAIR LOSS AND OTHER HYPERANDROGENIC CONDITIONS BIOPHYSICA, INC. (US) 2002-01-09 EP disclosed
EP-1144366-A2 USE OF ANDROGEN RECEPTOR SUPPRESSORS BIOPHYSICA, INC. (US) 2001-10-17 EP disclosed
WO-2001058855-A1 USE OF ANDROGEN RECEPTOR SUPPRESSORS BIOPHYSICA, INC (US) 2001-08-16 WO disclosed
WO-2001058854-A1 A TOPICAL ANTIANDROGEN FOR HAIR LOSS AND OTHER HYPERANDROGENIC CONDITIONS BIOPHYSICA, INC. (US) 2001-08-16 WO disclosed
US-6184249-B1 Androgen receptor suppressors in the therapy and diagnosis of prostate cancer, alopecia and other hyper-androgenic syndromes BIOPHYSICA, INC. 2001-02-06 US disclosed
WO-2000037430-A2 USE OF ANDROGEN RECEPTOR SUPPRESSORS BIOPHYSICA, INC. (US) 2000-06-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295142-A1 NOVEL COMPOUNDS AS HISTONE DEACETYLASE 6 INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC6, HDAC1, HDAC2 AR 788/4885MMP13 1064/4885PDK2 646/4885
US-12570646-B2 Compounds as histone deacetylase 6 inhibitor, and pharmaceutical composition comprising the same HDAC6, HDAC3, HDAC1 AR 316/4885MMP13 662/4885PDK2 2122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.